To cardiologist Dr. Steven Nissen of the Cleveland Clinic, who wasn’t involved in the trial but is leading a similar one of tirzepatide, those effects are all evidence of the benefits of weight loss.
Tirzepatide has shown greater levels of weight loss than semaglutide in clinical trials, leading many, including Nissen, to hope it will show even stronger cardiovascular benefits.
Importantly, participants didn’t have a history of diabetes; a previous trial had shown that treating people with diabetes with a GLP-1 drug, Ozempic, reduced their cardiovascular risk.
The Wegovy trial showed that 569 of 8,803 people taking the drug had a heart attack or stroke or died from heart-related causes, or 6.5%.
The amount of weight loss seen in the trial, 9.4%, was less than in other studies of Wegovy, which showed average weight loss closer to 15%.
Persons:
Ania Jastreboff, Wegovy, Dr, Amit Khera, National Institutes of Health’s Dr, Tiffany M, Powell, Wiley, Eli Lilly, Steven Nissen, wasn’t, ” Nissen, “, Tirzepatide, Nissen, Michael Lincoff, Lincoff, ”, Jastreboff, Sanjay Gupta, hadn’t, “ semaglutide
Organizations:
CNN, Nordisk’s Wegovy, American Heart Association, Yale Obesity Research Center, University of Texas Southwestern Medical Center Dallas, National Institutes of Health’s, New England, of Medicine, US Food and Drug, Cleveland Clinic, Novo Nordisk, Cleveland, CNN Health
Locations:
Philadelphia, Powell